Are Benzonate (Benzonatate) pearls safe to use in patients with heart failure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Safety of Benzonatate Pearls in Heart Failure Patients

Benzonatate pearls can be used safely in heart failure patients as they are not specifically contraindicated in the major heart failure guidelines and do not appear on lists of medications that worsen heart failure.

Medications to Avoid in Heart Failure

  • NSAIDs and COX-2 inhibitors are explicitly contraindicated in heart failure patients due to their potential to increase the risk of heart failure worsening and hospitalization (Class III recommendation, Level B evidence) 1
  • Thiazolidinediones (glitazones) are not recommended in heart failure patients as they increase the risk of heart failure worsening and hospitalization (Class III recommendation, Level A evidence) 1
  • Diltiazem, verapamil, and other calcium channel blockers should be avoided in patients with heart failure with reduced ejection fraction (HFrEF) due to their negative inotropic effects 1
  • Adaptive servo-ventilation is not recommended in patients with HFrEF and predominant central sleep apnea due to increased mortality risk 1

Benzonatate Safety Profile

  • Benzonatate is a non-narcotic antitussive that works as a local anesthetic by anesthetizing stretch receptors in the lungs, thereby reducing the cough reflex 2
  • Unlike opioid-based cough suppressants, benzonatate does not have respiratory depressant effects that could potentially worsen heart failure symptoms 2
  • Benzonatate does not appear on the American Heart Association's list of medications that may cause or exacerbate heart failure 3, 4
  • The European Society of Cardiology guidelines do not list benzonatate among medications contraindicated in heart failure 1

Considerations When Using Benzonatate in Heart Failure

  • Standard dosing of benzonatate (100-200 mg three times daily) is unlikely to affect cardiac function 2
  • Overdose of benzonatate can cause serious cardiac complications including cardiac arrest, as reported in case studies, so proper patient education about adherence to prescribed dosing is essential 2
  • Patients should be monitored for any signs of allergic reactions or unusual side effects, especially during initial treatment 2

Alternative Cough Management in Heart Failure

  • Non-pharmacological approaches should be considered first, including proper positioning, adequate hydration, and addressing underlying causes of cough 5
  • If pharmacological treatment is necessary, benzonatate is preferable to opioid-based cough suppressants, which can cause respiratory depression 2

Common Pitfalls to Avoid

  • Failing to recognize that some medications commonly used for symptom management can worsen heart failure (such as NSAIDs) 1, 4
  • Not considering potential drug interactions with heart failure medications when prescribing new treatments 3
  • Overlooking the possibility that persistent cough might be a symptom of worsening heart failure or an adverse effect of ACE inhibitors rather than an independent condition requiring treatment 5

Conclusion

While benzonatate is not specifically mentioned in heart failure guidelines, it does not appear on lists of medications that worsen heart failure and can be considered a safer alternative to opioid-based cough suppressants for heart failure patients requiring cough relief.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Cardiac Arrest Due to Benzonatate Overdose.

The American journal of case reports, 2019

Research

The Use of Drugs that Should be Avoided or Used with Caution in Patients Hospitalized for Acute Decompensated Heart Failure.

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2024

Guideline

Management of Orthopnea and Paroxysmal Nocturnal Dyspnea in Heart Failure

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.